https://www.selleckchem.com/pr....oducts/iclepertin.ht
We demonstrate similar findings in both anti-CTLA-4/PD-1 combination therapy, and in anti-PD-1 inhibitor-associated colitis. On the basis of our data we successfully targeted this pathway in a patient with refractory ICI-colitis, using the JAK inhibitor tofacitinib. IFNγ-producing CD8 T cells are a pathological hallmark of ICI-colitis, and a novel target for therapy. IFNγ-producing CD8+ TRM cells are a pathological hallmark of ICI-colitis, and a novel target for therapy.Temozolomide is a first-line therapeutic drug for glioblastoma (
Like
Comment
Share
